Drugs / SMT-NK
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03937895 | Dec 2019 → Jun 2021 | biliary tract cancer | SMT bio Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05429697 | Jun 2022 → Jan 2025 | biliary tract cancer | SMT bio Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SMT-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05429697 ↗ |
| Modality | Cell therapy | “'SMT-NK' Inj (allogeneic Natural Killer cell)” NCT03937895 ↗ |
| Route | Intravenous | “weekly administration via Intravenous for 2 weeks” NCT03937895 ↗ |